NEW YORK (GenomeWeb News) – Natera today announced a US distribution deal with pathology services provider ProPath for Natera's Panorama non-invasive prenatal screening test.

The test uses a blood draw to detect trisomy 21, 18, and 13, as well as monosomy X, triploidy, and sex chromosome aneuploidies. It employs Natera's algorithm called Next Generation Aneuploidy Testing Using SNPs to analyze cell-free DNA from both the mother and the fetus.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Rare gene mutations are guiding the search for drugs to manage chronic pain without opioids, according to CNBC.

The new Francis Crick Institute building can get too noisy for some researchers to concentrate, according to the Guardian.

CBS News reports that there are still many vacancies at the White House Office of Science and Technology Policy, but that it's uncertain whether they will be filled.

In Nucleic Acids Research this week: pipeline to analyze and visualize bacterial genomes, database of global set of human genomes, and more.